MegaPro Biomedical Co

MegaPro Biomedical Co ROCE

The Return on Capital Employed (ROCE) of MegaPro Biomedical Co (6827.TWO) as of Nov 18, 2026 is -45.53 %. In the previous year, Return on Capital Employed (ROCE) was -88.18 % — a change of -48.36% (higher).

ROCE

-45.53 %

YoY

-48.36%

Last updated:

In 2025, MegaPro Biomedical Co's return on capital employed (ROCE) was -45.53 %, a -48.36% increase from the -88.18 % ROCE in the previous year.

The MegaPro Biomedical Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-33.06 TWD
Jan 1, 2020
-60.61 TWD
Jan 1, 2021
-24.88 TWD
Jan 1, 2022
-38.73 TWD
Jan 1, 2023
-52.21 TWD
Jan 1, 2024
-88.18 TWD
Jan 1, 2025
-45.53 TWD
The MegaPro Biomedical Co ROCE history
YEARROCEYoY
-45.53 %-48.36%
-88.18 %+68.89%
-52.21 %+34.81%
-38.73 %+55.66%
-24.88 %-58.95%
-60.61 %+83.36%
-33.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MegaPro Biomedical Co Stock analysis

What does MegaPro Biomedical Co do? MegaPro Biomedical Co., Ltd. generates revenue through its development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's primary products are MPB-1514, MPB-1523, MPB-1734, and MPB-2043, each targeting specific medical conditions. MPB-1514 treats anemia in chronic kidney disease patients via intravenous injection, while MPB-1523 diagnoses hepatocellular carcinoma through intravenous administration. MPB-1734 addresses solid tumors with intravenous treatment, and MPB-2043 aids in diagnosing metastases in peripheral lymph nodes of cancer sites. These products are sold to healthcare providers and medical institutions requiring advanced diagnostic and therapeutic solutions. The company focuses on two core technology platforms: nanoparticle and nanocell, which underpin its product development. Its product portfolio targets chronic kidney disease, hepatocellular carcinoma, solid tumors, and cancer metastasis diagnostics. These applications are directed toward medical professionals and facilities specializing in oncology and nephrology. The firm's revenue model relies on the commercialization of these specialized drug ingredients for targeted medical treatments and diagnostics. MegaPro Biomedical's products are designed for intravenous use across various medical conditions, positioning the company within the biotechnology sector. Its revenue streams come from the sale of these proprietary drug ingredients to hospitals, clinics, and research institutions. The company's market segments include healthcare providers treating kidney disease, cancer diagnostics, and oncology-focused medical facilities seeking innovative therapeutic solutions. MegaPro Biomedical Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling MegaPro Biomedical Co's Return on Capital Employed (ROCE)

MegaPro Biomedical Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing MegaPro Biomedical Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

MegaPro Biomedical Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in MegaPro Biomedical Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about MegaPro Biomedical Co stock

Return on Capital Employed (ROCE) of MegaPro Biomedical Co is -45.53 % in 2025.

Return on Capital Employed (ROCE) of MegaPro Biomedical Co changed from -88.18 % to -45.53 %, representing a -48.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) MegaPro Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s MegaPro Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — MegaPro Biomedical Co

All Key Metrics — MegaPro Biomedical Co